Pd-L1 Testing Based on The SP142 Antibody in Metastatic Triple-Negative Breast Cancer: Summary of an Expert Round-Table Discussion

Figures & data

Table 1. Most common commercially available monoclonal PD-L1 antibodies for immunohistochemical analysis to assess the expression of PD-L1 considering US FDA approvals for non-small-cell lung cancer.

PD-L1 antibody	Drug	IHC assay	Cut-off	Line	Approval status
22C3	Pembrolizumab	DAKO Autostainer Link 48 platform (Agilent Inc)	TPS ≥1%	1L2L	• FDA: companion • CE-IVD
					• FDA: companion • CE-IVD
28-8	Nivolumab	DAKO Autostainer Link 48 platform (Agilent Inc)	TC ≥1%	2L	• FDA: complementary • CE-IVD
SP142	Atezolizumab	VENTANA BenchMark Ultra platform (Ventana Medical Systems Inc)	TC ≥50% and/or IC ≥10%	1L	• FDA: companion • CE-IVD
			TC ≥1 % and/or IC ≥1%	2L	• FDA: complementary • CE-IVD
SP263	Durvalumab	VENTANA BenchMark Ultra platform (Ventana Medical Systems Inc)	TC ≥1%	1L maintenance, in unresectable stage III after chemoradiation therapy	• FDA: complementary/companion • CE-IVD: companion
	Nivolumab		TC ≥1%	2L	• CE-IVD
	Pembrolizumab		TC ≥50%	1L	• CE-IVD
73-10	Avelumab	DAKO Autostainer Link 48 platform (Agilent Inc)	TC ≥1 %	2L	• NA

CE-IVD: European Commission in vitro diagnostic; IC: Immune cell; IHC: Immunohistochemistry; TC: Tumor cell; TPS: Tumor proportion score; NA: Not approved; 1L: First line; 2L: Second line.

Reproduced from [24].

Figure 1. Analysis of agreement between pathologists in the Spanish PD-L1 (SP142) triple-negative breast cancer training program.

Box plot by case ID for immune cell percentage. PD-L1 (SP142) assay triple-negative breast cancer mean proficiency trainee test scores compared with expert consensus scores and case-level agreement. Scores for each case were averaged across a total of 83 pathologists who attended the training program. The median for each dataset is indicated by the black center line, and the first and third quartiles are the edges of the box area, which is known as the IQR. The extreme values (within 1.5-times the IQR from the upper or lower quartile) are the ends of the lines extending from the IQR (circles). Points at a greater distance from the median than 1.5-times the IQR are plotted individually as asterisks. These points represent potential outliers.

IC: Immune cell; IQR: Interquartile range.

Figure 2. Proposed PD-L1 testing algorithm in metastatic triple-negative breast cancer.

Lantuejoul S , Sound-TsaoM, CooperWAet al. PD-L1 testing for lung cancer in 2019: perspective from the IASLC Pathology Committee. J. Thorac. Oncol.15(4), 499–519 (2020).

 PubMed Web of Science ®Google Scholar